Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

330

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

October 31, 2011

Study Completion Date

September 30, 2020

Conditions
Thyroid Cancer
Interventions
DRUG

XL184

Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily

DRUG

Placebo

Gelatin capsules color and size-matched to XL184 capsules administered orally daily

Trial Locations (113)

18015

St. Luke's Hospital & Health Network, Bethlehem

19104

Hospital of the University of Pennsylvania, Philadelphia

20010

Washington Cancer Institute, Washington D.C.

21287

Johns Hopkins University, Baltimore

23601

Peninsula Cancer Institute, Newport News

29425

Hollings Cancer Center, Charleston

33612

H. Lee Moffet Cancer Center and Research Institute, Tampa

35294

University of Alabama at Birmingham, Comprehensive Cancer Center, Birmingham

37232

Vanderbilt University Medical Center, Nashville

43210

Ohio State University, James Cancer Hospital, Columbus

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

48202

Henry Ford Health System, Detroit

52242

University of Iowa, Iowa City

55905

Mayo Clinic, Rochester

60637

University of Chicago, Chicago

63110

Washington University School of Medicine, St Louis

65109

Capitol Comprehensive Cancer Care Clinic and Research Institute, Jefferson City

66160

Kansas University Medical Center, Kansas City

68114

Nebraska Methodist Hospital, Omaha

72205

University of Arkansas for Medical Sciences, Little Rock

80045

University of Colorado Cancer Center, Aurora

85258

TGEN Clinical Research Service at Scottsdale Healthcare, Scottsdale

90095

UCLA, Los Angeles

91505

Burbank

94305

Stanford Cancer Center, Stanford

97239

Oregon Health & Science University, Portland

06520

Yale University, School of Medicine, New Haven

02114

Massachusetts General Hospital, Boston

05401

Vermont Cancer Center at Fletcher Allen Health Care, Burlington

Unknown

Klagenfurt

Multiple site locations, Vienna

Cliniques Universitaires St. Luc, Brussels

Universitair Ziekenhuis, Leuven

Brasília

Lajeado

Porto Alegre

Multiple site locations, São Paulo

Calgary

Toronto

CHUM - Hopital Saint-Luc, Montreal

Sherbrooke

Santiago

Odense

Angers

Bordeaux

Lyon

Marseille

Reims

Villejuif

Klinik fuer Nuklearmedizin des Universitaetsklinikums Essen, Essen

Gemeinschaftspraxis, Heidelberg

Universitaetsklinikum Leipzig, Leipzig

Johannes-Gutenberg Universitaet Mainz, Mainz

Klinikum der Ludwig-Maximilians-Universitaet Muenchen, München

Ludwig-Maximilians-Universitaet Muenchen, München

Universitaetsklinikum Tuebingen, Tübingen

Universitaetsklinikum Wuerzburg, Würzburg

Athens

Kidwai Institute of Oncology, Bangalore

Indo-American Cancer Institute and Research Center, Hyderabad

SEAROC Cancer Institute, S.K. Soni Hospital, Jaipur

Netaji Subhash Chandra Bose Cancer Hospital Research Institute, Kolkata

Central India Cancer Research Institute, Nagpur

Shatabdi Superspeciality Hospital, Nashik

All India Institute of Medical Sciences, New Dehli

Deenanath Mangeshkar Hospital & Research Center, Pune

Ruby Hall Clinic, Pune

Haifa

Jerusalem

Petah Tikva

Tel Aviv

Florence

Milan

Naples

Pisa

Rome

Siena

Turin

Amsterdam

Groningen

Leiden

Multiple site locations, Lima

Bydgoszcz

Gliwice

Pozan

Szczecin

Warsaw

Coimbra

Porto

Obninsk

Ufa

Voronezh

Yaroslavl

Riyadh

Multiple site locations, Seoul

Multiple site locations, Barcelona

Madrid

Murcia

Santiago de Compostela

Seville

Valencia

Gothenburg

Lund

Uppsala

Bern

Geneva

Cardiff

Glasgow

London

Manchester

Newcastle upon Tyne

Oxford

Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Exelixis

INDUSTRY

NCT00704730 - Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer | Biotech Hunter | Biotech Hunter